HIGH-RISK PROSTATE CANCER

This phase 2 trial tests a combination of hormone therapy (Lupron), an androgen blocker (Darolutamide), and an immunotherapy (Pembrolizumab) given before and after prostate removal surgery in 40 men with high-risk prostate cancer. The goal is to see if this approach can reduce or…

This study tests a new type of radiation therapy for men with high-risk prostate cancer that hasn't spread. The treatment uses advanced imaging to deliver higher radiation doses directly to the main tumor while also treating the whole pelvis. Researchers want to see if this appro…

This study tests two types of targeted radiation therapy (177Lu-PSMA-617 and 225Ac-PSMA-617) in 45 men with high-risk prostate cancer who are scheduled for prostate removal surgery. The goal is to see which therapy delivers more radiation to the tumor and how it affects the immun…

This phase 2 trial tests whether adding the targeted drug capivasertib to standard hormone therapy can shrink or destroy high-risk prostate tumors before surgery. The study enrolls 30 men with PTEN-loss prostate cancer, a marker of resistance to standard treatment. Participants r…

This study tests a precise type of radiation called proton therapy for men with high-risk prostate cancer that has spread to lymph nodes. The goal is to see if targeting the tumor and nearby lymph nodes with protons causes fewer bowel and urinary side effects than standard radiat…

This phase 2 trial tests a new radiation approach for men with high-risk or locally advanced prostate cancer. It combines hypofractionated radiotherapy (fewer, larger doses) with a microboost that delivers extra radiation to the most aggressive tumor spots. The goal is to improve…

This early-phase trial is testing whether giving epigenetic therapy before prostate removal can make the cancer more visible to the immune system. About 20 men with high-risk prostate cancer will receive the drugs before their scheduled prostatectomy. The main goals are to check …

This phase II trial is testing whether using a special PET/MR scan (PSMA) to guide radiation therapy can improve outcomes for men with high-risk prostate cancer. Fifty participants will receive targeted radiation boosts to areas identified by the scan. The main goal is to see if …

This study tests a new radioactive drug called Tb-PSMA given before surgery to remove the prostate in men with high-risk prostate cancer. The goal is to see if it is safe and helps improve surgical outcomes. About 20 participants will receive the drug and then undergo standard pr…

This study tests a new way to do PET scans for men with high-risk prostate cancer. Instead of two full CT scans, it uses one CT plus a delayed PET-only image, which may lower radiation exposure. Researchers will check if the delayed images match the standard ones well enough. The…

This study is for men with intermediate- or high-risk prostate cancer who will receive hormone therapy and radiation. Researchers want to see if using a special PET scan (PSMA PET) during hormone therapy can help doctors better target remaining cancer with radiation while avoidin…

This study is testing whether a special type of scan called PSMA PET can better monitor how prostate cancer responds to treatment. Researchers will scan 110 men with high-risk prostate cancer before and after treatment to see if changes in the scan match standard measures like PS…

This study looks at how people with BRCA1/2 gene mutations react to additional genetic risk testing for prostate cancer. Researchers want to understand how this information affects their decisions about cancer screening. The study involves 150 men aged 45-70 who carry a BRCA1/2 m…